CoChat
Cited by 190

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study

Open access
Imazio, Massimo, Andreis, Alessandro, De Ferrari, Gaetano Maria, Cremer, Paul C, Mardigyan, Vartan, Maestroni, Silvia, Luis, Sushil Allen, Lopalco, Giuseppe, Emmi, Giacomo, Lotan, Dor, Marcolongo, Renzo, Lazaros, George, De Biasio, Marzia, Cantarini, Luca, Dagna, Lorenzo, Cercek, Andreja Cerne, Pivetta, Emanuele, Varma, Beni, Berkson, Laeora, Tombetti, Enrico, Iannone, Florenzo, Prisco, Domenico, Caforio, Alida Linda P, Vassilopoulos, Dimitrios, Tousoulis, Dimitrios, De Luca, Giacomo, Giustetto, Carla, Rinaldi, Mauro, Oh, Jae K, Klein, Allan L, Brucato, Antonio, Adler, Yehuda · 2020 · European Journal of Preventive Cardiology

Abstract

Aims: Novel therapies are needed for recurrent pericarditis, particularly when corticosteroid dependent and colchicine resistant. Based on limited data, interleukin-1 blockade with anakinra may be beneficial. The aim of this multicentre registry was to evaluate the broader effectiveness and safety of anakinra in a ‘real world’ population. Methods and results: This registry enrolled consecutive patients with recurrent pericarditis who were corticosteroid dependent and colchicine resistant and treated with anakinra. The primary outcome was the pericarditis recurrence rate after treatment. Secondary outcomes included emergency department visits, hospitalisations, corticosteroid use and adverse events. Among 224 patients (46 ± 14 years old, 63% women, 75% idiopathic), the median duration of disease was 17 months (interquartile range 9–33). Most patients had elevated C-reactive protein (91%) and pericardial effusion (88%). After a median treatment of 6 months (3–12), pericarditis recurrences were reduced six-fold (2.33–0.39 per patient per year), emergency department admissions were reduced 11-fold (1.08–0.10 per patient per year), hospitalisations were reduced seven-fold (0.99–0.13 per patient per year). Corticosteroid use was decreased by anakinra (respectively from 80% to 27%; P < 0.001). No serious adverse events occurred; adverse events consisted mostly of transient skin reactions (38%) at the injection site. Adverse events led to discontinuation in 3%. A full-dose treatment duration of over 3 months followed by a tapering period of over 3 months were the therapeutic schemes associated with a lower risk of recurrence. Conclusion: In patients with recurrent pericarditis, anakinra appears efficacious and safe in reducing recurrences, emergency department admissions and hospitalisations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/2047487319879534

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 190

Metadata

Authors
Imazio, M., Andreis, A., De Ferrari, G. M., Cremer, P. C., Mardigyan, V., Maestroni, S., Luis, S. A., Lopalco, G., Emmi, G., Lotan, D., Marcolongo, R., Lazaros, G., De Biasio, M., Cantarini, L., Dagna, L., Cercek, A. C., Pivetta, E., Varma, B., Berkson, L., Tombetti, E., Iannone, F., Prisco, D., Caforio, A. L. P., Vassilopoulos, D., Tousoulis, D., De Luca, G., Giustetto, C., Rinaldi, M., Oh, J. K., Klein, A. L., Brucato, A., & Adler, Y.
Venue
European Journal of Preventive Cardiology
Published
2019-10-15
Volume
27
Issue
9
Pages
956-964
ISSN
  • 2047-4873 (ISSN-L)
  • 2047-4881
OpenAlex
W2981072868
Cited by
190
References
1
FWCI
13.69
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study. https://app.cochat.ai/papers/10.1177/2047487319879534
The paper
Imazio, M., Andreis, A., De Ferrari, G. M., Cremer, P. C., Mardigyan, V., Maestroni, S., Luis, S. A., Lopalco, G., Emmi, G., Lotan, D., Marcolongo, R., Lazaros, G., De Biasio, M., Cantarini, L., Dagna, L., Cercek, A. C., Pivetta, E., Varma, B., Berkson, L., . . . Adler, Y. (2020). Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study. European Journal of Preventive Cardiology. https://doi.org/10.1177/2047487319879534

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.